MedImmune Venture Fund: Up To $100M For Biotech
Hard market times did not deter MedImmune Inc. from putting together a venture capital subsidiary that the company said will invest up to $100 million in other biotechnology firms. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.